In recent years, Invisalign has become one of the most sought-after orthodontic solutions in Singapore. With its clear aligners, discreet appearance, and modern treatment approach, Invisalign appeals to both working professionals and teenagers who want straighter teeth without traditional metal braces.

However, many patients are surprised when they start comparing prices and notice a significant variation in the Invisalign cost in Singapore between clinics.

Some dental practices quote prices that seem affordable, while others charge considerably more for what appears to be the same treatment. This disparity often leads to confusion and hesitation. Understanding why Invisalign pricing differs from clinic to clinic can help patients make informed decisions, avoid hidden costs, and select a provider that delivers both safety and results.

This article explores the real factors behind Invisalign pricing in Singapore, breaking down what you are truly paying for and why cheaper is not always better when it comes to orthodontic care.

Understanding Invisalign Treatment in Singapore

Invisalign is not a one-size-fits-all dental service. It is a customized orthodontic treatment that relies on advanced technology, clinical expertise, and ongoing patient monitoring. Each aligner is designed using digital scans of the patient’s teeth and adjusted gradually to guide tooth movement over time.

In Singapore, Invisalign treatments must be prescribed and supervised by licensed dental professionals. The process typically includes consultation, 3D imaging, treatment planning, aligner fabrication, and multiple follow-up visits. These elements directly influence the Invisalign cost in Singapore and explain why prices are not standardized across all clinics.

Key Factors That Influence Invisalign Cost in Singapore

Dentist’s Experience and Accreditation

One of the most significant pricing factors is the dentist’s level of training and experience with Invisalign. Dentists who have completed advanced Invisalign certifications or have treated a high volume of cases often charge more for their services. Their fees reflect not only technical expertise but also the ability to handle complex orthodontic issues effectively.

Experienced Invisalign providers typically offer more accurate treatment planning, reduced risk of complications, and better long-term outcomes. While less experienced clinics may offer lower prices, patients may face longer treatment times or additional corrective procedures.

Case Complexity and Treatment Duration

Not all Invisalign cases require the same level of correction. Minor spacing issues or mild crowding often fall under Invisalign Express or Lite plans, which cost less. In contrast, patients with severe crowding, bite misalignment, or jaw issues require comprehensive treatment plans involving more aligners and longer durations.

Complex cases demand more chair time, frequent monitoring, and potential refinements. These additional resources directly increase the Invisalign cost in Singapore for more advanced orthodontic needs.

Technology and Diagnostic Tools Used

Clinics that invest in modern dental technology often charge higher fees. Advanced tools such as iTero digital scanners, 3D treatment simulations, and AI-assisted treatment planning significantly enhance accuracy and comfort.

Traditional dental impressions can still be used, but they are less precise and may require adjustments later. Clinics offering state-of-the-art diagnostics often deliver smoother treatment experiences, fewer delays, and more predictable results, which justify the higher Invisalign cost in Singapore.

Clinic Location and Operating Costs

Location plays a subtle but important role in Invisalign pricing. Dental clinics located in central business districts or premium medical hubs often face higher rental, staffing, and operational costs. These overheads influence service pricing, including orthodontic treatments.

However, a higher price does not always equate to better care. Patients should assess the clinic’s credentials, technology, and treatment approach rather than focusing solely on location-based pricing differences.

What’s Included in the Treatment Package

One common reason for pricing discrepancies is what the quoted Invisalign fee actually includes. Some clinics advertise lower prices but exclude essential services that later increase the final cost.

A comprehensive Invisalign package may include:

• Initial consultation and digital scans
• Custom aligners and refinements
• Regular follow-up appointments
• Retainers after treatment completion

Clinics offering all-inclusive packages often appear more expensive upfront but may provide better overall value and cost transparency.

The Importance of Follow-Up Care and Monitoring

Invisalign treatment requires consistent monitoring to ensure teeth move as planned. Clinics that emphasize follow-up care often schedule regular reviews and make timely adjustments when needed.

Lower-cost clinics may reduce the number of included visits, which can compromise treatment quality. Adequate monitoring ensures safe tooth movement, reduces discomfort, and minimizes the risk of relapse, all of which are critical considerations when evaluating Invisalign cost in Singapore.

Invisalign vs Traditional Braces: Cost Perspective

While Invisalign generally costs more than conventional braces, many patients in Singapore consider it a worthwhile investment. Invisalign aligners are removable, easier to clean, and significantly less noticeable. These benefits often translate into improved oral hygiene and greater confidence during treatment.

From a cost perspective, Invisalign also reduces emergency visits associated with broken wires or brackets. Over time, this can offset part of the higher initial expense, especially for adults with busy schedules.

How to Choose the Right Invisalign Provider in Singapore

Selecting the right clinic involves more than comparing prices. Patients should prioritize clinical expertise, treatment transparency, and patient reviews. A reputable Invisalign provider will explain the treatment process clearly, discuss realistic outcomes, and provide a detailed cost breakdown.

Asking the right questions during consultation can reveal whether the quoted Invisalign cost in Singapore aligns with the quality of care offered. Trust and communication between patient and dentist are essential for successful orthodontic tre atment.

Invisalign Cost Transparency and Patient Expectations

Clear communication about pricing helps manage patient expectations and build trust. Clinics that explain why certain treatments cost more demonstrate professionalism and ethical practice.

Patients should be cautious of clinics that promise unusually low prices without discussing treatment complexity or long-term outcomes. Invisalign is a medical procedure, not a cosmetic shortcut, and quality care should always take priority.

Key Takeaways on Invisalign Cost in Singapore

Understanding the factors behind Invisalign pricing empowers patients to make informed decisions. The Invisalign cost in Singapore reflects a combination of professional expertise, technology, treatment complexity, and clinic standards.

Choosing a clinic based solely on price may lead to compromises in care quality. Patients who invest in experienced providers often benefit from smoother treatments, predictable outcomes, and long-term dental health.

In Singapore’s competitive dental landscape, trusted providers such as Nuffield Dental emphasize clinical excellence, transparent pricing, and patient-centered care, helping individuals achieve confident smiles with peace of mind.

Frequently Asked Questions (FAQs)

1. What is the average Invisalign cost in Singapore?

The Invisalign cost in Singapore typically ranges from SGD 4,500 to SGD 9,000, depending on case complexity, treatment duration, and clinic expertise.

2. Why is Invisalign more expensive at some clinics?

Higher prices often reflect advanced technology, experienced orthodontists, comprehensive treatment packages, and thorough follow-up care.

3. Does insurance cover Invisalign treatment in Singapore?

Most dental insurance plans in Singapore do not fully cover Invisalign, but some corporate or premium plans may offer partial orthodontic benefits.

4. Are cheaper Invisalign options safe?

Lower-cost Invisalign treatments can be safe if provided by licensed and experienced dentists. Patients should ensure the clinic includes proper monitoring and refinements.

5. How long does Invisalign treatment usually take?

Treatment duration varies, but most Invisalign cases in Singapore take between 12 to 24 months, depending on the severity of misalignment.

A prediction market company best known for allowing users to bet on world events is stepping into New York City’s food scene — if only briefly — with the launch of what it’s calling the city’s first-ever free grocery store.

Polymarket will be open for New Yorkers in Lower Manhattan starting at 12PM from Feb. 12 through Feb. 16, according to the NYC for Free website. It’s being described as the city’s first free grocery store, “fully stocked” and requiring no purchase.

Polymarket posted on X, Tuesday, that the idea took “months of planning.” In addition to paying for the lease, the company said it had donated $1 million to Food Bank For New York City to support “an organization that changes how our city responds to hunger.”

MYSTERY BETTOR WON $400K PREDICTING MADURO CAPTURE BEFORE U.S. FORCES MOVED IN: REPORT

Daily hours and the grocery store’s closing date are subject to change, according to the website.

An inside view of The Polymarket shows the variety of free food available. (Photo courtesy of Polymarket)

Photos on social media show the market offering a variety of food staples — from produce, milk, eggs and bread to brand-name snacks such as Pringles, Sour Patch Kids and Oreo cookies.

Polymarket did not immediately respond to Fox News Digital’s request for comment on why it is opening what it calls the city’s first free grocery store.

The store is located in downtown Manhattan.

The announcement comes just days after rival Kalshi made a similar move, when owner George Zoitas gave hundreds of shoppers at Westside Market in the East Village $50 each toward their groceries.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

The bold marketing tactics by both Polymarket and Kalshi may be seen as a nod to New York City Mayor Zohran Mamdani’s pledge to open government-run grocery stores. Mamdani told Fox News Digital during his campaign that it will be possible for a “partnership” between the city and grocery store and bodega owners, despite his plan to open five city-run stores.

Mamdani appeared to poke fun at the announcement in an X post on Wednesday afternoon, replying directly to Polymarket’s post with a photo of a satirical headline that read, “Heartbreaking: The worst person you know just made a great point.”

READ MORE FROM FOX BUSINESS

This article was written by

Follow

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Indian stocks, Desai argues in a strategy report, now offer an unusual mix of “inexpensive relative valuations, poor trailing performance, strong policy stimulus and a consequent growth upcycle, an undervalued currency, weak foreign positioning and potentially a new buyback cycle.”

The 12-month trailing performance is “the worst in history” even as relative valuations are “approaching previous troughs”, with foreign portfolio investor (FPI) positioning having weakened steadily over the past four years. “India could be a pain trade, which may just accelerate the returns on stocks,” the report notes, adding that an undervalued rupee and a friendlier tax regime are likely to trigger “more buybacks” and keep net equity supply modest.

On the macro front, Morgan Stanley sees “a sharp turn in earnings growth over the coming months” as India’s growth cycle accelerates on the back of a coordinated reflation effort by the Reserve Bank of India and the government. The report cites the combination of rate cuts, bank deregulation, liquidity infusion, continued capex, tax reductions and a “relatively stimulating budget” as evidence that “India’s hawkish macro set-up post-Covid is now unwinding.”

Trade deals and a thaw in relations with China are seen as additional tailwinds to growth and risk appetite.

Live Events

This macro backdrop feeds directly into the re-rating argument. Desai highlights that “the falling intensity of oil in GDP and rising share of exports in GDP, especially services, and fiscal consolidation imply a lower saving imbalance,” which in turn should allow “structurally lower real rates.”
At the same time, lower inflation volatility, driven by supply-side reforms and flexible inflation targeting, should mean “volatility in interest rates and growth rates is likely falling in coming years.” Morgan Stanley’s base case sets a December 2026 Sensex target of 95,000, implying upside of 13% and a trailing P/E of 23.5 times, above the 25-year average of 22 times, to reflect “greater confidence in the medium-term growth cycle in India, India’s lower beta, a higher terminal growth rate and a predictable policy environment.” The base case rests on continued gains in macro stability through fiscal consolidation, increased private investment and a sustained positive gap between real growth and real rates, alongside “robust domestic growth, steady global growth and benign oil prices.”

The bull case, with a 30% probability, pegs the Sensex at 107,000 by December 2026, assuming oil prices “persistently below US$60 per barrel”, successful reflation that lifts growth estimates, and a curtailment of the global trade war, with Sensex earnings compounding at 19% annually over FY25–28.

Also Read | Gold and silver ETFs crash up to 10% for the second day. What should investors do?

The bear case, assigned a 20% probability, takes the Sensex down to 76,000 if oil spikes above US$90 per barrel, the RBI is forced to tighten, global growth slows materially and the US slips into recession, with earnings growth moderating to 15% and equity multiples de-rating to reflect a weaker macro environment.

Underlying the optimism is a call that the earnings cycle is turning. The firm’s proprietary leading earnings indicator “is suggesting improving earnings growth”, while its composite valuation indicator, which blends 11 absolute and relative metrics, points to “equity returns of around 16% in the next 12 months.” Sensex earnings in the base case are projected to compound at 17% annually through FY28, with the top-down framework for the broader market showing EPS growth of 22% in FY26, 20% in FY27 and 17% in FY28.

Positioning and sentiment are the other key pillars of the re-rating thesis. India’s weight in global emerging market funds relative to its MSCI EM weight, and FPIs’ shareholding gap between the top 75 companies and the broader market, suggest “India could be the pain trade in 2026” if global investors are forced to add to underweight positions. Morgan Stanley’s proprietary sentiment indicator, which combines flows, volatility, trading activity and breadth, is firmly in the “buy zone”, indicating a contrarian opportunity.

Meanwhile, the real effective exchange rate is near multi-year lows, historically a supportive backdrop for equities, even if the past relationship with stocks has weakened.

The portfolio stance reflects a conviction that a macro trade is now unfolding. “Domestic cyclicals over defensives and external-facing sectors,” the report says, with an overweight stance on financials, consumer discretionary and industrials, and underweight calls on energy, materials, utilities and healthcare.

Within sectors, the strategists argue that rising credit growth and low credit costs, a recovery in urban consumption and robust government as well as private capex make a strong case for domestic cyclicals to lead, while defensives and global cyclicals lag.

Desai sums up the backdrop as one where Indian equities are backed by policy, earnings and positioning, but not yet fully priced for the improving structural story. With “high growth with low volatility” and a gradual shift in household balance sheets towards equities, Morgan Stanley sees the conditions in place for Indian stocks to “enjoy a rare combination” that, in its view, justifies a re-rating over the next couple of years.

(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)

It’s not the model. It’s not the team. It’s the unit economics.

Venture capital poured a record $202 billion into AI startups in 2025, capturing half of all global funding. Yet the math remains brutal: 90% of AI companies will fail, a rate significantly higher than the 70% seen in traditional tech startups. According to Alexander Kopylkov, a venture capital investor focused on long-term business fundamentals, this failure rate is not driven by lack of innovation, but by broken unit economics. “Everyone can build a demo,” he notes. “The survivors are the ones who can build a business.”

The Burn Problem

Many AI startups at Series A are burning $2 to $5 for every $1 of new revenue. This burn multiple, a metric popularized by investor David Sacks, has become the defining number VCs scrutinize in 2026.

For context, top-performing SaaS companies operate at burn multiples below 1.5x. The gold standard is 1x or below: spend a dollar, earn a dollar.

Kopylkov breaks it down into first principles: AI startups face a structural cost problem that traditional software companies don’t. “Where a SaaS company spends 15-20% of revenue on infrastructure, AI companies often start at 40-50%,” he explains. “That gap has to close, or the company dies.”

The infrastructure burden isn’t the only culprit. AI startups also face escalating talent costs, with machine learning engineers commanding salaries that dwarf traditional software roles. Add in the constant need to retrain models, maintain data pipelines, and keep pace with rapidly evolving foundation models, and the cost structure becomes punishing.

What the Survivors Look Like

Citing data from multiple VC surveys, Kopylkov notes that companies achieving sub-1.5x burn multiples share three characteristics: disciplined hiring, laser focus on product-market fit before scaling, and AI-enhanced operational efficiency.

The survivors also share something else: enterprise customers. Anthropic, one of the few AI companies demonstrating sustainable economics, generates 70-80% of its revenue from enterprise clients. Its annualized revenue run rate grew from $87 million in early 2024 to $7-9 billion by late 2025, not through hype, but through solving compliance and safety problems that large institutions will pay for.

Kopylkov emphasizes that enterprise focus isn’t just about bigger contracts. “Enterprise customers have longer sales cycles, but they also have lower churn, higher lifetime value, and more predictable revenue,” he says. “That predictability is what lets you plan, hire, and scale without gambling your runway.”

For founders, Kopylkov recommends a simple framework: Before raising your next round, answer three questions. Is your burn multiple under 2x? Do you have 18+ months of runway? Are your gross margins above 50%, or trending there fast?

If the answer to any of these is no, investors in 2026 will notice. The due diligence has gotten sharper, and the patience for aspirational projections has worn thin.

The Consolidation Is Coming

The era of experimentation is ending. According to a TechCrunch survey of 24 enterprise-focused VCs, 2026 is the year enterprises start consolidating AI investments and picking winners.

Andrew Ferguson of Databricks Ventures put it plainly: “Today, enterprises are testing multiple tools for a single-use case. As enterprises see real proof points from AI, they’ll cut out some of the experimentation budget, rationalize overlapping tools, and deploy that savings into the AI technologies that have delivered.”

In his view, this consolidation will accelerate through 2026 and into 2027. The startups that survive won’t be the ones with the best pitch decks. They’ll be the ones with the clearest ROI.

For Kopylkov, this winnowing is inevitable. “When every startup claims to be AI-powered, the label becomes meaningless,” he says. “Buyers are getting smarter. They’re asking harder questions about what’s actually under the hood and whether the product delivers measurable value. The companies that can’t answer those questions convincingly won’t make it to 2027.”

The Opportunity in the Wreckage

Despite the grim statistics, Kopylkov sees opportunity. The 90% failure rate isn’t a reason to avoid AI, it’s a filter.

“The companies that get through are battle-tested,” he says. “They’ve proven they can acquire customers efficiently, retain them, and improve margins over time. That’s exactly what you want to invest in.”

Kopylkov compares this shift to the dot-com era: plenty of destruction, but the survivors like Amazon, Google, and eBay went on to define the next two decades of technology. The pattern is familiar: irrational exuberance, painful correction, and then durable growth built on real fundamentals.

The difference in 2026 is that investors aren’t waiting for the crash to demand fundamentals. They’re demanding them now. The funding environment has shifted from “move fast and figure it out” to “show me the numbers.”

For Kopylkov, this is healthy. “Capital discipline forces founders to think like operators, not just visionaries,” he says. “The best companies emerging from this period will have both.”

“2026 is a fundamentals-first year where capital rewards revenue growth, efficiency, and real AI advantage—and punishes anything that is AI veneer on old ideas.”
— Anders Ranum, Partner, Sapphire Ventures

For founders building AI companies today, the message is clear: the hype got you in the door. The unit economics will determine whether you stay.

President Donald Trump is set to officially unveil a new website called TrumpRx on Thursday evening, which his administration says will allow Americans to purchase prescription drugs at lower costs.

White House press secretary Karoline Leavitt said the announcement is scheduled for 7 p.m. EST and will feature Trump alongside CMS Administrator Dr. Mehmet Oz and National Design Studio Director Joe Gebbia.

“This historic announcement will save millions of Americans money,” Leavitt wrote on X. “You won’t want to miss it!”

CNN reported that at least 16 drug manufacturers have negotiated agreements with the administration to participate in TrumpRx, but specifics on available drugs and pricing remain unclear.

TRUMP SAYS $50B RURAL HEALTH PLAN FUNDED BY CUTTING MEDICAID ‘WASTE, FRAUD AND ABUSE’

President Donald Trump speaks in the Oval Office of the White House in Washington, D.C., on Tuesday, Sept. 30, 2025. (Francis Chung / Politico/Bloomberg via Getty Images / Getty Images)

The White House announced in December that Trump had reached agreements with nine major pharmaceutical companies, including Amgen, Merck, Novartis, Sanofi and Bristol Myers Squibb. 

The move was aimed at lowering prescription drug prices in the U.S. to match the lowest prices paid by other developed nations.

Several drugs listed in the White House announcement included high-cost medications used to treat diabetes, asthma, HIV, hepatitis C, multiple sclerosis and cardiovascular disease.

TrumpRx.gov signage in the Oval Office of the White House in Washington, D.C., on Friday, Oct. 10, 2025. (Shawn Thew / EPA/Bloomberg via Getty Images / Getty Images)

TOP 10 MOST EXPENSIVE PRESCRIPTION DRUGS IN THE US BY PRICE AND BY SALES VOLUME

Under the agreements, the companies committed to offering steep discounts on a range of medications for chronic and costly conditions, with some drugs sold directly to consumers at reduced prices through TrumpRx.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

For example, Bristol Myers Squibb will reduce the price of its HIV medication, Reyataz, from $1,449 to $217 for patients purchasing directly through TrumpRx, and Merck will reduce the price of its diabetes medication, Januvia, from $330 to $100.

The administration said the deals were expected to save Americans billions of dollars while expanding access to lower-cost medications.

Bitcoin experienced a significant plunge in early Asia trading on Friday, falling as much as 4.8% to US$60,033, reaching its lowest level since October 2024. This selloff effectively erased all gains booked by the token since United States President Donald Trump’s 2024 election victory.

However, the cryptocurrency later pared some of these losses, rising by over 2% to more than $64,400 by 9:12 am in Singapore.

• Current Price and Performance (as of Fri Feb 06 2026 11:25:01 GMT+0700):
  • Spot Price: The Bitcoin price against the US Dollar fluctuates slightly across sources, but the most frequently cited values are around 64,692.00 USD (from the main search result) and 64,601 USD (TradingView). Another source mentions $65,178.14 (Binance) and $64,039.06 (Revolut).

Other cryptocurrencies, such as Solana, also saw sharp declines before rebounding. This market downturn is largely attributed to a brutal series of liquidations that began in October, which significantly sapped market confidence. The selling intensified this week due to the unwinding of leveraged bets and broader market turbulence, with approximately $2.3 billion of leveraged long bets across all cryptocurrencies being liquidated within a 24-hour period.

Rachael Lucas, an analyst at BTC Markets, noted a distinct lack of market appetite to counter this liquidation-driven selloff. She highlighted that “repeated failures to hold support levels have shifted behaviour” and emphasized the critical importance of Bitcoin maintaining the $60,000 support level, warning that a failure to do so could lead to a further decline into the mid-$50,000 range. The market’s volatility also had a substantial impact on major Bitcoin holders, exemplified by Michael Saylor’s Strategy Inc, which reported a net loss of $12.4 billion for the fourth quarter, primarily driven by the mark-to-market decline in its extensive Bitcoin holdings.

The recent intensification of the cryptocurrency selloff is attributed to several specific factors:

• Brutal Series of Liquidations: The market has been on the back foot since a brutal series of liquidations began in October, which significantly sapped market confidence.
• Unwinding of Leveraged Bets: This week, the selling picked up steam due to the unwinding of leveraged bets.
• Broader Market Turbulence: Alongside the unwinding of leveraged bets, broader market turbulence also contributed to the intensified selling this week.
• Lack of Market Appetite: Rachael Lucas, an analyst at BTC Markets, noted a distinct lack of market appetite to step in front of this move, particularly given its liquidation-driven nature.
• Repeated Failures to Hold Support Levels: Lucas also highlighted that “repeated failures to hold support levels have shifted behaviour,” impacting market sentiment and trading actions.

The financial metric that quantifies this activity is:

• Approximately $2.3 billion of leveraged long bets across all cryptocurrencies were liquidated within a 24-hour period.

Market analysts suggest that the initial drop in Bitcoin’s value may have been triggered by broader concerns over tightening monetary policies and regulatory scrutiny in key markets. Despite the rebound, volatility remains high, with traders closely monitoring developments in global financial markets. Additionally, other major cryptocurrencies, including Ethereum and Binance Coin, also saw fluctuations, reflecting a broader trend of uncertainty across the digital asset space. Investors are advised to exercise caution as the market continues to respond to external economic pressures and evolving sentimen

Other People are Reading

Alphabet executives struck a confident tone on Wednesday’s post-earnings call, signaling that Google’s heavy investments in artificial intelligence are now translating into real revenue growth across the business.

The call was the first since Google released its Gemini 3 model, which has boosted user engagement and helped the company regain momentum in the intensifying AI race.

While executives did not name OpenAI directly, the message to investors was clear: Google’s AI push is no longer just about experimentation – it is delivering returns across search, cloud and enterprise products.

That confidence is underpinning Alphabet’s willingness to dramatically increase spending. Executives said the company is considering capital expenditures of between $175 billion and $185 billion in 2026 to expand AI computing capacity, a forecast that initially rattled investors.

APPLE SEES BIGGEST SALES JUMP IN 4 YEARS, POWERED BY ‘STAGGERING’ IPHONE DEMAND

Sundar Pichai, the CEO of Google’s parent company, Alphabet. (Brandon Wade/Reuters / Reuters)

“Overall, we’re seeing our AI investments and infrastructure drive revenue and growth across the board,” CEO Sundar Pichai said.

The scale of that growth is now visible across the company. Alphabet reported more than $400 billion in annual revenue for the first time, underscoring the strength of its core businesses even as it pours money into AI infrastructure.

SPOTIFY NOW REPRESENTS ONE-THIRD OF THE MUSIC INDUSTRY’S TOTAL RECORDED REVENUE IN 2025

Google’s Gemini app surpassed 750 million monthly active users by the end of the October through December quarter, up from 650 million in the prior period. While it still trails OpenAI’s ChatGPT – which its CEO said has more than 800 million weekly users – Pichai said engagement has risen sharply since the Gemini 3 launch.

Gemini 3 is now embedded into Google’s search experience and powers its enterprise AI offerings, which have reached 8 million paying licenses, according to the company.

AI assistant apps on a smartphone – OpenAI ChatGPT, Google Gemini, and Anthropic Claude. (Getty Images)

Investor nerves over the capex surge eased as results came in. Google Cloud revenue jumped 48% in the quarter, reinforcing Wall Street’s view that Alphabet’s AI investments are driving tangible growth rather than speculative spending.

The stock initially fell as much as 6% in after-hours trading before stabilizing, reflecting a broader message from investors: massive AI spending will be tolerated only if it produces clear financial returns.

Alphabet’s financial strength gives it an edge in that environment. With a deep cash position and multiple profit engines – from search and YouTube to cloud services – the company is better positioned than many rivals to sustain the enormous costs of the AI arms race.

OpenAI CEO Sam Altman speaks during the Microsoft Build conference at the Seattle Convention Center Summit Building in Seattle, Washington. (Jason Redmond/Getty Images)

Since early last year, Alphabet has gone from perceived laggard to leader among the “Magnificent Seven” tech giants, now rivaled only by Nvidia and Apple in market value. By contrast, growing investor unease around OpenAI’s costly expansion has highlighted the appeal of Alphabet’s scale, profitability and balance-sheet firepower.

CLICK HERE TO GET FOX BUSINESS ON THE GO

“If you are software and you are connected to OpenAI, you’re doubly not intriguing to people,” said Eric Clark, portfolio manager of the LOGO ETF. “Right now, Google has the hot hand.”